Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer
LUGANO-MADRID, 10 September, 2017 - Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemot..






